Positive results from Elan and Biogen

PHARMACEUTICAL group Elan and its partner Biogen have reported positive results after 12 months’ trading of its Antegren treatment for multiple sclerosis.

In a study of 942 patients, the Antegren drug treatment reduced the rate of relapses in sufferers of the disease by a figure of 66%. As a result, the two companies have submitted applications for the approval of Antegren as an MS treatment in the US, EU, Canada and Australia.

These results follow a 12-month trial using Antegren. Two-year figures will be available in the first half of 2005, Elan said.